DEFENSIN THERAPEUTICS ApS: Financial statements 2024
CVR: 35513280
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
DEFENSIN THERAPEUTICS ApS (CVR 35513280) has filed annual accounts for 2024. In 2024, the company reported a net result of DKK -130,534 compared with DKK -425,344 the year before. Equity in the 2024 report amounted to DKK 1,313,495. The solvency ratio was 97.1%.
- Profit/Loss
- DKK -130,534
- Equity
- DKK 1,313,495
- Total Assets
- DKK 1,352,370
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | - | -131K | 1.3M | - |
| 2023 | - | - | -425K | 1.4M | - |
| 2022 | - | - | -474K | 1.7M | - |
| 2021 | 0 | - | -366K | 2.1M | - |
| 2020 | - | - | -2.3M | 2.5M | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
DEFENSIN THERAPEUTICS ApS has published its annual report for 2023. The net result was DKK -425,344.
About DEFENSIN THERAPEUTICS ApS
DEFENSIN THERAPEUTICS ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Peter Hviid Nordkild. The board consists of Ejner Bech Jensen (chair), Matthew Alister Cooper, Peter Hviid Nordkild and Robert Ehehalt. The company's owners include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437.